> **Original:** [[PDFs/Pitch-Decks/Performant Investor Overview.pdf|View Original PDF]]

Converting PDF to images...
Extracted 26 pages
Sending to Claude Haiku for extraction...
---
source_pdf: "../../PDFs/Pitch-Decks/Performant Investor Overview.pdf"
type: pitch-deck
ingested: 2025-12-20
original_filename: Performant Investor Overview.pdf
---

> **Original:** [[../../PDFs/Pitch-Decks/Performant Investor Overview.pdf|View Original PDF]]

## Page 1

**Text:**
PERFORMANT

INVESTOR PRESENTATION

2025 Company Overview

This document is for educational purposes only and may be updated and this information is provided "as is" without any expressed or implied warranty. Rights and obligations discussed in relation to the information in these materials are non-binding unless and until the parties enter into a signed, legally binding agreement.

**Images/Charts/Diagrams:**
[LOGO: Performant company logo with stylized horseshoe-like symbol in blue]

---

## Page 2

**Text:**
FORWARD LOOKING STATEMENTS

This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues and adjusted EBITDA in 2025 as well as illustrative future revenues and adjusted EBITDA margins; our commercial client growth strategy; our estimated revenue from commercial programs implemented; our ability to implement our first state government contract; our ability to scale our business through contract awards and implementations and the expected benefits of integrating workflow efficiencies including through investment in artificial intelligence software, natural language processing technologies and other technology initiatives. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to generate revenue following long implementation periods associated with new customer contracts; client relationships and the Company's ability to maintain such client relationships; many of the Company's customer contracts are subject to periodic renewals; are not exclusive; do not provide for committed business volumes; anticipated trends and challenges in the Company's business and competition in the markets in which it operates; the Company's indebtedness and compliance, or failure to comply, with restrictive covenants in the Company's credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company's ability to hire and retain employees with specialized skills that are required for its business; down-turns operations and other liquidity needs; the impact of public health emergencies, such as the COVID-19 pandemic, on the Company's business and operating opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company's operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company's third-party vendors and subcontractors; the adaptability of the Company's technology platform to new markets and processes; the Company's ability to invest in and utilize our data and analytics capabilities to expand its capabilities; the Company's growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company's ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company's ability to comply with and adapt to industry regulations and compliance demands.

More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2024 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this presentation and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[LOGO: Performant company logo at bottom right]

---

## Page 3

**Text:**
Performant At A Glance

PHLT
Nasdaq listed        ~$220M Market cap²        900+ FTEs        $4-5B Serviceable Revenue Opportunity

Mission

We are driven by a singular purpose—to transform the healthcare ecosystem by addressing more than $300 billion¹ in healthcare payment integrity. Our unwavering mission is to pioneer innovative solutions that redirect these funds towards enhancing patient care—an effort that aligns with the current administration's commitment to rooting out fraud, waste, and abuse.

What is Healthcare Payment Integrity?

Payment Responsibility    Clinical Appropriateness

Billing Accuracy         Contract Compliance

Why does it exist?

Complex Coding          New Reimbursement Models

Disparate Data          Evolving Demographics

¹Source: JAMA "Waste in the US Health Care System: Estimated Costs and Potential for Savings
²As of 12/31/2024

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[LOGO: Performant company logo]
[DIAGRAM: Shows healthcare payment integrity components in oval shapes - Payment Responsibility, Clinical Appropriateness, Billing Accuracy, Contract Compliance under "What is Healthcare Payment Integrity?" and Complex Coding, New Reimbursement Models, Disparate Data, Evolving Demographics under "Why does it exist?"]

---

## Page 4

**Text:**
Complex Industry Leads to Complex Solutions
Performant has the tools to address multiple payment errors and growing medical costs

COMPLEX CODING
Multiple coding standards to adhere to

NEW REIMBURSEMENT MODELS
Complicated contract arrangements

DISPARATE DATA
• Providers lack information about payer contracts and patient coverage
• Includes structured, unstructured and reference data

EVOLVING DEMOGRAPHICS
Ageing demographic and growing population covered by insurance

PERFORMANT

CLAIMS-BASED SERVICES
• Is this billed and coded accurately?
• Does this meet coding standards?
• Is this contract compliant?

ELIGIBILITY-BASED SERVICES
• Is the correct party paying this claim?

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Shows four problem areas (Complex Coding, New Reimbursement Models, Disparate Data, Evolving Demographics) pointing to Performant's two solution categories (Claims-Based Services and Eligibility-Based Services)]

---

## Page 5

**Text:**
Emerging Leader In Large And Growing Market
Saved clients over $2B in last three years

Projected National Health Expenditures¹

$4.9T                                   $7.8T
$1.2T                                   $1.9T

2023                                    2032

■ Projected Waste ■ Projected National Health Expenditures ($B)

100%
90%     Administrative 
        Complexity
80%
70%
60%     Inefficient
        Care
50%
40%
30%     Payment
        Integrity     PERFORMANT
20%
10%
0%

~20% of healthcare spend considered waste²

¹Source: CMS, National Health Expenditure Data Projections - 2022
²Source: JAMA, "Waste in the US Health Care System: Estimated Costs and Potential for Savings" - 2019

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[CHART: Bar chart showing projected national health expenditures growth from 2023 ($4.9T total with $1.2T waste) to 2032 ($7.8T total with $1.9T waste)]
[CHART: Stacked bar chart showing breakdown of healthcare waste - Administrative Complexity at top (~30%), Inefficient Care in middle (~40%), and Payment Integrity at bottom (~20%) with Performant logo positioned in the Payment Integrity section]

---

## Page 6

**Text:**
Market Sizing
Claims processing is complex and inefficient, resulting in a meaningful market opportunity

$4-5B Serviceable Revenue Opportunity

~$4.9T     US Healthcare Spend

~$1.2T     Waste in Healthcare¹

~$300B     Payment Integrity Space

~$25-30B   Addressable Opportunity²

$4-5B      Serviceable Revenue Opportunity³

Federal Government
$500M-1B
Addressable

State Government
$300-500M
Addressable

Commercial
$3.2-3.5B
Addressable

¹Source: JAMA "Waste in the US Health Care System: Estimated Costs and Potential for Savings" - 2019
²Management estimates of addressable inaccurate payments; exclusion examples include: missed work and structurally not addressable 
³Management estimates based on blended hit and fee rates

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Funnel chart showing market sizing from $4.9T US Healthcare Spend at top, narrowing down through Waste in Healthcare ($1.2T), Payment Integrity Space ($300B), Addressable Opportunity ($25-30B), to Serviceable Revenue Opportunity ($4-5B) at bottom]
[DIAGRAM: Rectangle showing breakdown of $4-5B opportunity by segment - Federal Government, State Government, and Commercial with their respective addressable amounts]

---

## Page 7

**Text:**
Significant Government Backbone
Started with Government and has become a bellwether for commercial payers

Headline Federal Government Wins

Q2 2025: Expected decision on RAC Region 5 Re-compete and Opportunities for Regions 3 and 4

October 2024: Awarded New York State RAC contract – first state award

DECEMBER 2022: Re-awarded Medicare Secondary Payer Commercial Repayment Center (MSP CRC) contract

MARCH 2022: Awarded CMS RAC Region 2 for 8.5-years

FEBRUARY 2022: Announced HHS OIG IDIQ contract win

APRIL 2021: Re-awarded CMS RAC Region 1 for 8.5-years

Led to Meaningful Commercial Traction

33% of 2024 Commercial Audit Savings Derived from our oldest RAC Region

103 Commercial Implementations in last 36 months

Existing Commercial Clients grew 35% on average since 2021

Commercial vs Government Revenue Growth
45% 3-yr CAGR

$55.5                 $58.2          $66.9
                      $56.5  $49.9   $51.4
                      $36.5

$22.0

2021                 2022           2023           2024

■ Commercial    ■ Government    ......... Linear (Commercial)

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TIMELINE: Vertical timeline showing government wins from April 2021 to Q2 2025]
[CHART: Stacked bar chart showing commercial vs government revenue from 2021-2024, with commercial revenue growing from $22.0M to $66.9M and government revenue fluctuating between $36.5M-$58.2M]

---

## Page 8

**Text:**
Unique Approach
Components required to effectively address payment integrity are complex—Performant offers a fresh approach

CLIENT-CENTRIC BUSINESS MODEL
• Shared savings business model
• Business process outsourcing
• Customizable solutions
• Focus on independence and quality

PROPRIETARY DATA ASSETS
• 200+ million lives of eligibility data
• 10+ years of claims, rules, and contract data

TECHNOLOGY STACK
• Purpose built for healthcare claims
• Advanced workflow, data analytics, and automation features

INDUSTRY EXPERTISE AND INNOVATION
• Medical directors, data analysts and payment integrity experts working together on real world solutions
• Concerted focus on developing new payment integrity concepts to increase client savings and reduce pain points

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Four connected pillars showing Performant's approach - Client-Centric Business Model (dark blue), Proprietary Data Assets (light blue), Technology Stack (green), and Industry Expertise and Innovation (orange), with arrows indicating flow between them]

---

## Page 9

**Text:**
Payment Integrity Landscape
High barriers to entry and consolidation results in less competition

INDUSTRY CREDIBILITY

INFORMATION SECURITY

COMPLIANCE

TECHNOLOGY

DATA

PERFORMANT
Optum EXL
COTIVITI
gainwell

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Circular diagram with Performant logo in center, surrounded by competitor logos (Optum, EXL, Cotiviti, Gainwell), with five segments around the outside labeled: Industry Credibility, Technology, Data, Compliance, and Information Security]

---

## Page 10

**Text:**
Multiple Avenues Of Growth
Successful track record of growth

LAND AND EXPAND

Expand Concepts
✓ Adopt new products
Cross-Sell Services
✓ Sell new services to existing eligibility clients
Add Volume
✓ Add Medicare Advantage line of business
✓ Add new region for a national payer

NEW CLIENTS

National (8M+ members)
✓ Currently have 5 of top 7 as clients
Middle Market (500k-8M members)
✓ Currently have approximately 20% of market as clients

ADJACENT MARKETS
✓ Tackle other buckets of healthcare waste through M&A

INNOVATION
✓ SaaS development for smaller health plans
✓ AI & NLP workflow gains

Land and Expand Example:
(savings)                +$100m

[CHART: Bar chart showing growth from 2016 to 2024, with increasing bar heights]

Initial Partnership: National Payer
› Acute & DME Audit products for Medicare Advantage lives

Growing Partnership
› 2019 – Added Managed Medicaid lives
› 2020 – Added new Audit product type
› 2020 – Cross-sold Eligibility product
› 2023 – Added new Eligibility product
› 2023 – Added new Audit product type

New Clients
Implemented 4 new logos in 2024

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Four-quadrant circular flow diagram showing Land and Expand, New Clients, Adjacent Markets, and Innovation as growth strategies]
[CHART: Bar chart showing growth example from 2016-2024 with increasing savings amounts reaching +$100m]

---

## Page 11

**Text:**
Financial Highlights
Demonstrates Strong Growth and Operational Rigor

STRONG HEALTHCARE REVENUE GROWTH
Healthcare Revenues

$118.3
$106.4
$94.7
$77.5

2021    2022    2023    2024

Strategic focus on healthcare growth and penetrating this massive market

COST CONSCIOUS
Operational Expenses
$132.5
$125.7    $116.1    $119.9

2021    2022    2023    2024

Maintained operational discipline to generate efficiencies while growing

INVESTED FOR FUTURE GROWTH
Commercial Implementations

42
41

23    21

2021    2022    2023    2024

Unique offering has led to strong sales, fueling tomorrow's growth

NIMBLE CAPITAL STRUCTURE
Debt on Balance Sheet

$20.0    $19.5

$5.0    $8.0

2021    2022    2023    2024

Financial flexibility to continue to grow

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[CHART: Four bar charts showing:
1. Healthcare Revenues growing from $77.5M (2021) to $118.3M (2024)
2. Operational Expenses fluctuating from $125.7M (2021) to $132.5M (2024)
3. Commercial Implementations growing from 23 (2021) to 42 (2024)
4. Debt on Balance Sheet varying from $20.0M (2021) to $8.0M (2024)]

---

## Page 12

**Text:**
Performant Healthcare Evolution
Started as a Division now a disruptive and scaling business

2012 ——— 2021 ——— 2025 On

Innovation:
✓ Data Engine
✓ Product Development
✓ Government Footprint
✓ Commercial Entrance

Growth:
✓ Commercial Expansion
✓ Federal Government Re-awards
✓ State Government Entrance
✓ Further Product Development

Profitability:
✓ AI / NLP Roadmap
✓ Workflow Efficiencies
✓ Scale Contract Wins

Target 20% Adj. EBITDA Margins

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TIMELINE: Shows progression from 2012 to 2021 to 2025 On, with three phases - Innovation (dark blue arrow), Growth (light blue arrow), and Profitability (green arrow) leading to target of 20% Adj. EBITDA Margins in a green star burst]

---

## Page 13

**Text:**
2025 Adj. EBITDA Growth

Discrete investments and Record new implementations masking profitability potential

$4.4M

$9.1 – 12.1M    $13.5 – 16.5M    $3.0 – 4.0M    $1.5M    $1.0-2.0M    $8.0 – 9.0M

2024 Adj. EBITDA    Operational Expansion    Illustrative Adj. EBITDA    Commercial Implementations    NY RAC Implementation    Technology Investments    2025 Adj. EBITDA Guidance

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[CHART: Waterfall chart showing progression from 2024 Adj. EBITDA ($4.4M) through various components: Operational Expansion ($9.1-12.1M), Illustrative Adj. EBITDA ($13.5-16.5M), then subtracting Commercial Implementations ($3.0-4.0M), NY RAC Implementation ($1.5M), and Technology Investments ($1.0-2.0M) to reach 2025 Adj. EBITDA Guidance ($8.0-9.0M)]

---

## Page 14

**Text:**
Margin Expansion
Path to Adj. EBITDA Margin Expansion

Scale
Natural ability to grow record contract implementations currently subscale

✓ 100+ Commercial contracts implemented since 2022
✓ NY State RAC
✓ CMS RAC Region 2

Efficiency Gains
Workflow and Technology Advancements

✓ AI / NLP Investments
✓ Workflow rationalization

$131 – $135M of revenue    2025 Revenue Guidance    Scale    Efficiency Gains    Target Future State

Scaled adj. EBITDA margin potential built off scale and Efficiency Gains

$150 – $160M of revenue

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Two-step progression showing current state ($131-$135M revenue) moving through Scale and Efficiency Gains to Target Future State ($150-$160M revenue). Scale section lists commercial contracts and RAC regions. Efficiency Gains section lists AI/NLP investments and workflow rationalization.]

---

## Page 15

**Text:**
Investment Highlights
Why Performant

Best-in-class platform utilizes proprietary technology and AI to gain efficiencies and margin expansion    ~200M eligible lives in PHLT data assets

Industry leading player in a multi-billion dollar, growing, highly monitored and increasingly complex healthcare payment integrity industry    $300B+ Payment Integrity Space

Strong sales and implementation pipeline provides confidence and visibility into future revenue growth as continued market share gains demonstrate our ability to compete in a highly competitive market    45%+ 3-year commercial healthcare revenue CAGR

Asset-light model with diverse, long-term client relationships that have resulted in attractive and visible operating leverage that can drive toward 20%+ EBITDA margins    ~300bps Adj. EBITDA margin expansion expected in 2025

Dynamic management team with combined +100 years of experience and deep ties to government and private payers across the healthcare landscape with sticky relationships    900+ Professionals focused on payment integrity

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Five horizontal arrows of different colors pointing to statistical achievements: ~200M eligible lives, $300B+ Payment Integrity Space, 45%+ 3-year commercial healthcare revenue CAGR, ~300bps Adj. EBITDA margin expansion expected in 2025, and 900+ Professionals focused on payment integrity]

---

## Page 16

**Text:**
APPENDIX

**Images/Charts/Diagrams:**
[IMAGE: Blurred motion photograph of city lights and traffic trails, suggesting speed and movement]

---

## Page 17

**Text:**
Illustrative Contract Ramp
Example of investment required to ramp with a contract ($/M)

CLAIMS BASED
~47% of 2024 healthcare revenue

$0.0
$0.3    $1.0
$(0.2)    0%    40%
    $0.4
INVESTMENT    BREAK-EVEN    STEADY STATE
0-12 MONTHS    12-30 MONTHS    30+ MONTHS

• Access to client systems
• Implement client policies and customizations
• Letter series and provider education
• Volume growth and recoveries begin to offset

• Scale volume and edits
• Adjust staffing needs

• Optimize value through policy and content library edits
• Retraining staff needs

Revenue
Gross Profit
Margin

ELIGIBILITY BASED
~53% of 2024 healthcare revenue

$0.0
$0.2    $0.5
$(0.1)    0%    55%
    $0.3
INVESTMENT    BREAK-EVEN    STEADY STATE
0-6 MONTHS    6-12 MONTHS    12+ MONTHS

• Access to client data and systems
• Implement client into our propriety data assets
• Payer outreach, setup, and coordination
• Testing

• Scale volume
• Adjust staffing needs

• Enrich data assets and expand payer connections
• Denial management and process optimization
• Retraining staff needs

Revenue
Gross Profit
Margin

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[CHART: Two parallel timelines showing contract ramp phases for Claims Based and Eligibility Based services, with revenue/profit progression from investment phase through break-even to steady state, including specific dollar amounts and margin percentages]

---

## Page 18

**Text:**
Major Contract Wins and Ramp Illustration
Example of revenue and profitability ramp for major contract wins

|                    | 2024 | 2025 | 2026 | 2027 | 2028 |
|-------------------|------|------|------|------|------|
| 2022 Commercial Implementations (20 @ ~$10m ACV) | [Pattern showing negative then positive margins] | [Green profitable sections] | [Green profitable sections] | [Green profitable sections] | [Green profitable sections] |
| CMS RAC Region 2 | [Mixed pattern] | [Mixed pattern] | [Green profitable sections] | [Green profitable sections] | [Green profitable sections] |
| 2023 Commercial Implementations (41 @ ~$18m ACV) | [Pattern showing investment then break-even] | [Mixed pattern] | [Green profitable sections] | [Green profitable sections] | [Green profitable sections] |
| 2024 Commercial Implementations (42 @ ~$18m+ ACV) | [Pattern showing investment] | [Mixed pattern] | [Mixed pattern] | [Green profitable sections] | [Green profitable sections] |
| NY State Medicaid RAC | [Pattern showing investment] | [Mixed pattern] | [Mixed pattern] | [Green profitable sections] | [Green profitable sections] |

Negative Operating Margins | Revenue Progress
Positive Operating Margins

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TABLE: Visual timeline showing profitability ramp for different contract groups from 2024-2028, using patterns to show negative margins (red/striped), revenue progress (black/striped), and positive margins (green) across the years]

---

## Page 19

**Text:**
Payment Integrity: Medical Cost Savings
1 in 5 medical claims are processed incorrectly

Intake & Prep → Check Eligibility → Select Provider → Determine Benefits → Validate Authorization → Price Claim → Remit Payment → Post Pay Audit

02 ELIGIBILITY                    01 CLAIMS AUDIT

Client Claims Data → 01 CLAIMS AUDIT → Obtain Medical Records → Audit Claims → Pre-pay: Cost Avoidance
                     Concepts to ID    Scoring &           
                     Claims           Selection            Post-pay: Offset/Recovery

Client Member Data → 02 ELIGIBILITY → Validate Coverage → Pre-pay: Report Primary → Pre-pay: Cost Avoidance
                     Eligibility      Benefit                      
                     Matching        Coordination       Post-pay: Bill Primary → Post-pay: Offset/Recovery

Note: Health Insurance Companies Process 1 in 5 Claims Wrong (capturebilling.com)

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Flow chart showing claims processing workflow from intake through post-pay audit, with two main service areas (Claims Audit and Eligibility) branching off to show their respective processes and outcomes]

---

## Page 20

**Text:**
Our Full Suite of Solutions

No Medical Records
• COB & Eligibility
• Provider Billing & Coding
• Contract Compliance
• System, Benefits & Policy

Medical Records
• DRG, Readmissions, Short Stay/Place of Service
• Outpatient APC, APG, ASC and Other
• DME, HIT, Home Health, Hospice
• High-Cost Drugs, Clinical Labs, Genetic Testing

• Premium Accuracy
• Payer Reclamation
• Provider Recovery
• Cost Avoidance

MSP Advantage

Data Mining Advantage

Claims Audit

Eligibility

TPL Advantage

Healthcare Solutions

• Payer Reclamation
• Rx Reclamation
• Provider Recovery
• Cost Avoidance

• Aged or Referred Debt
• Par/Non-Par
• Medicare Supplement

Claims or Audit-Based Reviews
Corrects claims that were billed inaccurately

$56.4MM        -23%
2024 Revenue   3-Year CAGR

Eligibility-Based Reviews
Identifies other insurance and coordinates coverage responsibility

$61.9MM        -8%
2024 Revenue   3-Year CAGR

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[DIAGRAM: Circular diagram showing healthcare solutions with different segments for Data Mining Advantage, MSP Advantage, TPL Advantage, Eligibility, Healthcare Solutions, and Claims Audit, with bullet points for each service category]

---

## Page 21

**Text:**
CONSOLIDATED BALANCE SHEET

(In thousands, except per share amounts)

|Assets| As of December 31,|
||2024|2023|
|Current assets:|||
|Cash and cash equivalents|$ 9,292|$ 7,252|
|Restricted cash||81|
|Trade accounts receivable, net of allowance for credit losses|14,165|17,584|
|Contract assets|10,876|10,879|
|Prepaid expenses and other current assets|3,991|3,651|
|Income tax receivable|34|335|
|Total current assets|38,358|39,782|
|Property, equipment, and software, net|14,021|9,724|
|Goodwill|47,372|47,372|
|Debt issuance costs|416|631|
|Right-of-use assets|826|531|
|Other assets|781|990|
|Total assets|$ 101,774|$ 99,030|

|Liabilities and Stockholders' Equity|||
|Current liabilities:|||
|Accrued salaries and benefits|$ 8,502|$ 7,924|
|Accounts payable|482|727|
|Other current liabilities|2,091|2,385|
|Contract liabilities|753|493|
|Estimated liability for appeals and disputes|317|601|
|Deferred asset acquisition payments|1,243|-|
|Lease liabilities|383|250|
|Total current liabilities|13,971|12,380|
|Long-term loan payable|8,000|5,000|
|Deferred asset acquisition payments|2,686|-|
|Lease liabilities|462|295|
|Other liabilities|156|648|
|Total liabilities|25,275|18,323|
|Commitments and contingencies|||
|Stockholders' equity:|||
|Common stock, $0.0001 par value. Authorized, 500,000 shares at December 31, 2024 and 2023, respectively; issued and outstanding, 78,309 and 76,920 shares at December 31, 2024 and 2023, respectively|$ -|$ -|
|Additional paid-in capital|151,688|146,001|
|Accumulated deficit|(75,197)|(65,302)|
|Total stockholders' equity|76,499|80,707|
|Total liabilities and stockholders' equity|$ 101,774|$ 99,030|

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TABLE: Consolidated Balance Sheet showing assets, liabilities, and stockholders' equity as of December 31, 2024 and 2023]

---

## Page 22

**Text:**
[This appears to be a blank page with only the page number "22" in the top right corner]

---

## Page 23

**Text:**
CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)
(unaudited)

|                    | Three Months Ended December 31, | Twelve Months Ended December 31, |
|                    | 2024 | 2023 | 2024 | 2023 |
|Revenues           | $ 34,766 | $ 32,567 | $ 122,981 | $ 113,743 |
|Operating expenses: |          |          |           |           |
|Salaries and benefits| 26,710   | 23,308   | 100,431   | 90,447    |
|Other operating expenses| 8,745    | 7,349    | 32,050    | 29,424    |
|Total operating expenses| 35,455   | 30,657   | 132,481   | 119,871   |
|Income (loss) from operations| (689)     | 1,910    | (9,500)   | (6,128)   |
|Gain on sale of certain recovery contracts| -        | -        | -         | 3         |
|Interest expense   | (307)    | (785)    | (1,105)   | (1,974)   |
|Interest income    | 99       | 154      | 359       | 240       |
|Loss before (benefit from) income taxes| (897)     | 1,279    | (10,246)  | (7,859)   |
|Provision for (benefit from) income taxes| (399)     | 24       | (351)     | (340)     |
|Net income (loss)  | $ (498)  | $ 1,255  | $ (9,895) | $ (7,519) |
|Net income (loss) per share attributable to common shareholders|          |          |           |           |
|Basic              | $ (0.01) | $ 0.02   | $ (0.13)  | $ (0.10)  |
|Diluted            | $ (0.01) | $ 0.02   | $ (0.13)  | $ (0.10)  |
|Weighted average shares|          |          |           |           |
|Basic              | 78,300   | 76,896   | 77,500    | 76,156    |
|Diluted            | 78,300   | 77,361   | 77,500    | 76,156    |

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TABLE: Consolidated Statements of Operations showing financial performance for three months and twelve months ended December 31, 2024 and 2023]

---

## Page 24

**Text:**
CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)
(unaudited)

|                    | For the Years Ended December 31, |
|                    | 2024 | 2023 |
|Cash flows from operating activities:|      |      |
|Net loss           | $ (9,895) | $ (7,519) |
|Adjustments to reconcile net loss to net cash provided by operating activities:|           |           |
|Loss on disposal of assets| 63       | 120       |
|Depreciation and amortization| 6,598    | 5,187     |
|Right-of-use assets amortization| 333      | 1,526     |
|Stock-based compensation| 5,881    | 3,936     |
|Amortization of debt issuance costs| 230      | 347       |
|Loss debt extinguishment| -        | 510       |
|Gain on sale of certain recovery contracts| -        | (3)       |
|Changes in operating assets and liabilities:|           |           |
|Trade accounts receivable| 3,419    | (1,790)   |
|Contract assets   | 3        | 581       |
|Prepaid expenses and other current assets| (340)    | 14        |
|Income tax receivable| 301      | 2,788     |
|Other assets      | 190      | 10        |
|Accrued salaries and benefits| 578      | 986       |
|Accounts payable  | (245)    | (535)     |
|Contract liabilities and other current liabilities| (549)    | 188       |
|Estimated liability for appeals and disputes| (84)     | (505)     |
|Lease liabilities | 289      | (1,759)   |
|Other liabilities | (492)    | (231)     |
|Net cash provided by operating activities| 6,178    | 3,860     |
|Cash flows from investing activities:|           |           |
|Purchase of property, equipment, and software| (7,010)  | (4,143)   |
|Proceeds from sale of certain recovery contracts| -        | -         |
|Net cash used in investing activities| (7,010)  | (4,140)   |
|Cash flows from financing activities:|           |           |
|Repayment of long-term loan payable| -        | (19,500)  |
|Debt issuance costs paid| (15)     | (1,156)   |
|Taxes paid related to net share settlement of stock awards| (194)    | (196)     |
|Borrowings from revolving loan| 3,000    | 5,000     |
|Net cash provided by (used in) financing activities| 2,791    | (15,852)  |
|Net increase (decrease) in cash, cash equivalents and restricted cash| 1,959    | (16,132)  |
|Cash, cash equivalents and restricted cash at beginning of year| 7,333    | 23,465    |
|Cash, cash equivalents and restricted cash at end of year| $ 9,292  | $ 7,333   |

|Reconciliation of the consolidated statements of cash flows to the consolidated balance sheets:|           |           |
|Cash and cash equivalents| $ 9,292  | $ 7,252   |
|Restricted cash  | -        | 81        |
|Total cash, cash equivalents and restricted cash at end of period| $ 9,292  | $ 7,333   |
|Non-cash investing activities:|           |           |
|Deferred asset acquisition payments| $ 3,929  | $ -       |
|Supplemental disclosures of cash flow information:|           |           |
|Cash (received) paid for income taxes| $ (94)   | $ (3,052) |
|Cash paid for interest| $ 670    | $ 1,291   |

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TABLE: Consolidated Statements of Cash Flows showing cash flow activities for years ended December 31, 2024 and 2023]

---

## Page 25

**Text:**
RECONCILIATION OF NON-GAAP RESULTS

(In thousands, except per share amounts)

|                    | Three Months Ended December 31, | Year Ended December 31, |
|                    | 2024 | 2023 | 2024 | 2023 |
|Reconciliation of Adjusted EBITDA:|      |      |      |      |
|Net income (loss)  | $ (498) | $ 1,255 | $ (9,895) | $ (7,519) |
|Provision for (benefit from) income taxes| (399)   | 24      | (351)     | (340)     |
|Interest expense⁽¹⁾| 307     | 785     | 1,105     | 1,974     |
|Interest income    | (99)    | (154)   | (359)     | (240)     |
|Stock based compensation| 1,759   | 1,121   | 5,881     | 3,936     |
|Depreciation and amortization| 1,354   | 1,382   | 6,598     | 5,187     |
|Severance expenses⁽²⁾| (8)     | 100     | 656       | 346       |
|Non-core operating expenses⁽⁴⁾| 701     | 15      | 737       | 52        |
|Gain on sale of certain recovery contracts⁽⁵⁾| -       | -       | -         | (3)       |
|Adjusted EBITDA    | $ 3,117 | $ 4,528 | $ 4,372   | $ 3,393   |

⁽¹⁾ Represents interest expense and amortization of debt issuance costs related to our Credit Agreement and prior credit agreement.
⁽²⁾ Represents amortization of debt issuance costs related to our Credit Agreement and prior credit agreement.
⁽³⁾ Represents severance expenses incurred in connection with a reduction in force for our nonhealthcare services.
⁽⁴⁾ Represents payments primarily related to legacy recovery business.
⁽⁵⁾ Represents gain on the sale of certain non-healthcare recovery contracts.
⁽⁶⁾ Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.
⁽⁷⁾ The Net loss for the three months ended December 31, 2024 was ($498), while the computation of adjusted net income results in adjusted net income of $1,321. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2024 includes dilutive common share equivalents of 1,584 added to the basic weighted average shares of 78,300. Similarly, net income for the three months ended December 31, 2023 was $1,255, and the computation of adjusted net income results in adjusted net income of $3,597. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2023 includes dilutive common share equivalents of 465 added to the basic weighted average shares of 76,896.

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TABLE: Reconciliation of Non-GAAP Results showing adjusted EBITDA calculation for three months and year ended December 31, 2024 and 2023]

---

## Page 26

**Text:**
RECONCILIATION OF NON-GAAP RESULTS (CONT'D)

(In thousands, except per share amounts)

|                    | Three Months Ended December 31, | Year Ended December 31, |
|                    | 2024 | 2023 | 2024 | 2023 |
|Reconciliation of Adjusted Net Income (Loss):|      |      |      |      |
|Net income (loss)  | $ (498) | $ 1,255 | $ (9,895) | $ (7,519) |
|Stock based compensation| 1,759   | 1,121   | 5,881     | 3,936     |
|Amortization of debt issuance costs⁽²⁾| 57      | 601     | 230       | 857       |
|Severance expenses⁽³⁾| (8)     | 100     | 656       | 346       |
|Non-core operating expenses⁽⁴⁾| 701     | 15      | 737       | 52        |
|Gain on sale of certain recovery contracts⁽⁵⁾| -       | -       | -         | (3)       |
|Tax adjustments⁽⁶⁾ | (690)   | 505     | (2,064)   | (1,427)   |
|Adjusted net income (loss)| $ 1,321 | $ 3,597 | $ (4,455) | $ (3,758) |

⁽¹⁾ Represents interest expense and amortization of debt issuance costs related to our Credit Agreement and prior credit agreement.
⁽²⁾ Represents amortization of debt issuance costs related to our Credit Agreement and prior credit agreement.
⁽³⁾ Represents severance expenses incurred in connection with a reduction in force for our nonhealthcare services.
⁽⁴⁾ Represents payments primarily related to legacy recovery business.
⁽⁵⁾ Represents gain on the sale of certain non-healthcare recovery contracts.
⁽⁶⁾ Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.
⁽⁷⁾ The Net loss for the three months ended December 31, 2024 was ($498), while the computation of adjusted net income results in adjusted net income of $1,321. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2024 includes dilutive common share equivalents of 1,584 added to the basic weighted average shares of 78,300. Similarly, net income for the three months ended December 31, 2023 was $1,255, and the computation of adjusted net income results in adjusted net income of $3,597. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2023 includes dilutive common share equivalents of 465 added to the basic weighted average shares of 76,896.

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TABLE: Reconciliation of Non-GAAP Results (continued) showing adjusted net income calculation for three months and year ended December 31, 2024 and 2023]

---

## Page 27

**Text:**
QUARTERLY AND ANNUAL REVENUE CONTRIBUTION BY LINE OF BUSINESS

(In thousands, except per share amounts)

|                    | For the Three Months Ended | For the Year Ended |
|                    | March 31, 2024 | June 30, 2024 | September 30, 2024 | December 31, 2024 | December 31, 2024 |
|Eligibility-based  | $ 13,388 | $ 14,264 | $ 16,070 | $ 18,138 | $ 61,860 |
|Claims-based       | 12,412   | 13,661   | 14,217   | 16,141   | 56,431    |
|Healthcare Total   | 25,800   | 27,925   | 30,287   | 34,279   | 118,291   |
|Customer Care / Outsourced Services| 1,534    | 1,437    | 1,232    | 487      | 4,690     |
|Total             | $ 27,334 | $ 29,362 | $ 31,519 | $ 34,766 | $ 122,981 |

|                    | For the Three Months Ended | For the Year Ended |
|                    | March 31, 2023 | June 30, 2023 | September 30, 2023 | December 31, 2023 | December 31, 2023 |
|Eligibility-based  | $ 12,480 | $ 14,131 | $ 18,165 | $ 16,403 | $ 61,179 |
|Claims-based       | 10,412   | 9,798    | 10,325   | 14,730   | 45,265    |
|Healthcare Total   | 22,892   | 23,929   | 28,490   | 31,133   | 106,444   |
|Recovery           | 19       | 14       | -        | -        | 33        |
|Customer Care / Outsourced Services| 2,818    | 1,542    | 1,472    | 1,434    | 7,266     |
|Total             | $ 25,729 | $ 25,485 | $ 29,962 | $ 32,567 | $ 113,743 |

|                    | For the Three Months Ended | For the Year Ended |
|                    | March 31, 2022 | June 30, 2022 | September 30, 2022 | December 31, 2022 | December 31, 2022 |
|Eligibility-based  | $ 14,214 | $ 12,417 | $ 13,142 | $ 13,511 | $ 53,284 |
|Claims-based       | 9,150    | 9,339    | 10,377   | 12,516   | 41,382    |
|Healthcare Total   | 23,364   | 21,756   | 23,519   | 26,027   | 94,666    |
|Recovery           | 118      | 7        | 41       | 75       | 241       |
|Customer Care / Outsourced Services| 3,601    | 3,918    | 3,618    | 3,140    | 14,277    |
|Total             | $ 27,083 | $ 25,681 | $ 27,178 | $ 29,242 | $ 109,184 |

© 2025 Performant. All rights reserved.

**Images/Charts/Diagrams:**
[TABLE: Quarterly and Annual Revenue Contribution by Line of Business showing revenue breakdown for 2024, 2023, and 2022 across different business segments]
